Open AccessThromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
Author(s) -
Yuri Vladimirovich Muravyev,
G I Gridina,
Д. Е. Каратеев
Publication year - 2013
Publication title -
naučno-praktičeskaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 1995-4492
pISSN - 1995-4484
DOI - 10.14412/1995-4484-2013-1514
Subject(s) - adalimumab , tumor necrosis factor alpha , tumor necrosis factor α , medicine , tumor necrosis factors , necrosis